Archives

Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial​Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial 

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 Phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.

Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer​Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer 

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the Phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.

Preoperative radiation may improve antitumor immune response in most common form of breast cancer​Preoperative radiation may improve antitumor immune response in most common form of breast cancer 

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of a Phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.